Clinical Trial Update: Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of irinotecan liposomes with nituzumab for recurrent/metastatic nasopharyngeal carcinoma after failure of fi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Irinotecan Liposome (Onivyde) (irinotecan liposome)
• Nituzumab (nituzumab)

Snippet

Sponsor: XIANG YANQUN | Conditions: Nasopharyngeal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING